About: Retrospective Multicenter Cohort Study Shows that Early Interferon Therapy is Associated with Favorable Clinical Responses in COVID-19 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Retrospective Multicenter Cohort Study Shows that Early Interferon Therapy is Associated with Favorable Clinical Responses in COVID-19 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Retrospective Multicenter Cohort Study Shows that Early Interferon Therapy is Associated with Favorable Clinical Responses in COVID-19 Patients
Creator	Xu, Yunsheng Yu, Hao Wang, Nan Lu, Yingying Wang, X Wang, F Liu, Feng Wang, Xiaolin Tong, M Liu, Z Wang, Shanshan Guo, S Lu, Z Peng, Hong Zhan, Y Zheng, Y Zou, X Wang, N Xu, G Cui, Miao Qian, Xiaosong Qiu, Feng Sciences, Health Cui, H Downstate, York Guo, Yabi Hou, Zhibing Song, F Song, Pinhong Tong, Gangling Wan, Deyun Wan, X Zhan, Yan Zheng, Zhihua Zhu, Linyu Zou, Xiafei
Source	Elsevier; Medline; PMC
abstract	Summary Interferons (IFN) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, recent report of ACE2, the host factor mediating SARS-Cov-2 infection, as interferon-stimulated, raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality compared to no IFN-α2b, while late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or CT scan improvement, while late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir (UFV) alone or together were associated with reduced mortality and accelerated recovery compared to lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 may induce favorable clinical responses.
has issue date	2020-07-18(xsd:dateTime)
bibo:doi	10.1016/j.chom.2020.07.005
bibo:pmid	32707096
has license	els-covid
sha1sum (hex)	1b890b31d97504c7accbae1c2c25cd70410c6763
schema:url	https://doi.org/10.1016/j.chom.2020.07.005
resource representing a document's title	Retrospective Multicenter Cohort Study Shows that Early Interferon Therapy is Associated with Favorable Clinical Responses in COVID-19 Patients
has PubMed Central identifier	PMC7368656
has PubMed identifier	32707096
schema:publication	Cell Host Microbe
resource representing a document's body	covid:1b890b31d97504c7accbae1c2c25cd70410c6763#body_text
is schema:about of	named entity 'infection' named entity 'mortality' named entity 'mortality' named entity 'ACE2' named entity 'umifenovir' named entity 'However' named entity 'retrospective' named entity 'Responses' named entity 'HOSPITAL' named entity 'COVID-19' named entity 'compared' named entity 'stage' named entity 'administration' named entity 'models' named entity 'Shows' named entity 'Cohort' named entity 'interferon' named entity 'CT scan' named entity 'COVID' named entity 'lopinavir/ritonavir' named entity 'umifenovir' named entity 'hospital discharge' named entity 'Cohort Study' named entity 'Multicenter' named entity 'Cohort Study' named entity 'COVID' named entity 'interferon-α2b' named entity 'diabetes' named entity 'IFN' named entity 'Interferon-α2b' named entity 'SARS-CoV-2' named entity 'IFN' named entity 'Log-rank test' named entity 'diabetes' named entity 'type I interferon' named entity 'eosinopenia' named entity '1.14' named entity 'infection' named entity 'cough' named entity 'symptom' named entity 'ACE2' named entity 'hypertension' named entity 'logistic regression' named entity 'IFN' named entity '95% CI' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software